Shares dropped 7.6% on concerns over intensifying pricing pressure in international markets and the planned exit from lower-margin Canadian consumer segments, signaling investor skepticism about near-term margin sustainability and strategic trade-offs.
Aurora Cannabis Inc. delivered a strong Q3 2026 performance with a 7% increase in net revenue, driven primarily by robust international medical cannabis growth. The company reported positive free cash flow and improved margins while focusing on strategic market exits to enhance profitability.